A Rare Sell Signal Emerges for Eli Lilly Amid Weight-Loss Drug Valuation Concerns

HSBC downgrades Eli Lilly, slashing price target on concerns over market size, price competition from new employer program, and inflated expectations for obesity drugs.

Eli Lilly’s valuation has soared to remarkable heights, fueled by intense investor enthusiasm surrounding its weight-loss medications. However, a stark warning from a major bank is now shifting investor focus toward the risks of an emerging price war and potentially inflated market expectations, triggering a significant analyst downgrade.

HSBC Sounds the Alarm on Valuation and Market Size

The catalyst for the recent share price movement was a decisive report from HSBC. The bank’s analysts downgraded their rating on Eli Lilly from "Hold" to "Reduce," simultaneously slashing their price target from $1,070 to $850. Their research contends that the company’s valuation now prices in absolute perfection, highlighting a widening gap between Wall Street's aggressive forecasts and a more conservative reality.

While the consensus view estimates the long-term obesity treatment market at over $150 billion, HSBC projects a substantially smaller market of $80 to $120 billion by 2032. The analysts also expressed skepticism about specific growth drivers, notably the anticipated oral drug, orforglipron. Although market projections suggest sales of around $1.5 billion for this drug by 2026, the bank cautioned that these figures may rely more on initial inventory builds rather than sustained patient demand. Furthermore, reliance on out-of-pocket payments could make the company's revenue stream more vulnerable to economic downturns.

Investors reacted swiftly to these concerns. In Tuesday's trading, the stock declined by 5.89 percent to €807.90, extending its year-to-date loss to over 12 percent.

Strategic Pivot Introduces Margin Pressure

Concurrently, Eli Lilly is pursuing a new strategy to expand patient access, which HSBC warns could compress future profitability. Through its recently launched "Employer Connect" program, the pharmaceutical giant is offering its weight-loss drug Zepbound to participating employers at a fixed net price of $449 per month. This direct-to-employer approach bypasses traditional intermediaries and aims to increase coverage among the approximately 80% of U.S. employers that currently do not reimburse for weight-management medications.

HSBC interprets this move as the starting point for an intense phase of price competition, which is likely to exert pressure on the industry's long-term profit margins. Despite this critical assessment from London, the broader analyst community remains predominantly bullish. Currently, 24 analysts still recommend buying the shares, with HSBC standing as the only major institution issuing a sell recommendation.

Eli Lilly itself maintains its forward-looking guidance, targeting total revenue between $80 and $83 billion for the year 2026.